Issues
Deals
Research
Ledger
About
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
Next issue
Issue 23 · Tue 17 Nov
All issues
Helus Pharma
Every issue covering Helus Pharma.
4 issues
2026-09-29
No. 16
Initiated in Q2. Unregistered at the end of Q3.
TRIALS
DEALS
REGULATORY
LILLY
ATAIBECKLEY
COMPASS
CYBIN
2026-07-14
No. 6
Compass just put a date on the first Western psychedelic launch: the first half of 2027.
TRIALS
ACCESS
COMPASS
CYBIN
2026-07-07
No. 5
European psychedelic depression development just split into two camps.
TRIALS
COMPASS
BECKLEY-PSYTECH
CYBIN
2026-06-23
No. 3
Europe's most advanced psychedelic Phase 3 is staked on the one indication that got harder last week.
TRIALS
RESEARCH
COMPASS
CYBIN